

Resource Summary Report

Generated by [NIF](#) on Sep 11, 2026

MKN7

RRID:CVCL_1417

Type: Cell Line

Proper Citation

RRID:CVCL_1417

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1417

Proper Citation: RRID:CVCL_1417

Description: Cell line MKN7 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric tubular adenocarcinoma

Defining Citation: [PMID:1933850](#), [PMID:3962675](#), [PMID:6862145](#), [PMID:11107048](#), [PMID:15723654](#), [PMID:15767549](#), [PMID:15900046](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22336246](#), [PMID:22460905](#), [PMID:24587255](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at p.Ile251Leu (c.751A>C) in PubMed=15900046., Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MKN7

Synonyms: MKN-7, MKN 7

Cross References: BTO:BTO_0002382, CLO:CLO_0050805, EFO:EFO_0002895, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472197, BioSample:SAMN03473201,

BioSample:SAMN10988431, cancercellines:CVCL_1417,
Cell_Model_Passport:SIDM00560, CGH-DB:118-1, CGH-DB:9020-4, ChEMBL-
Cells:ChEMBL3307377, ChEMBL-Targets:ChEMBL614355, CLS:305104,
Cosmic:733175, Cosmic:848370, Cosmic:877040, Cosmic:888825, Cosmic:889106,
Cosmic:897533, Cosmic:922693, Cosmic:924250, Cosmic:926112, Cosmic:968347,
Cosmic:983725, Cosmic:1007601, Cosmic:1066229, Cosmic:1093297, Cosmic:1187284,
Cosmic:1223587, Cosmic:1436024, Cosmic:1460708, Cosmic:1482077, Cosmic:1518242,
Cosmic:1995511, Cosmic:2807634, Cosmic-CLP:924250, DepMap:ACH-000678,
EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:924250, GEO:GSM552365,
GEO:GSM562401, GEO:GSM827584, GEO:GSM844608, GEO:GSM887326,
GEO:GSM888402, GEO:GSM1237677, GEO:GSM1237702, GEO:GSM1670114,
IARC_TP53:13723, IARC_TP53:21641, JCRB:FDSC0010, JCRB:JCRB0082,
JCRB:JCRB1025, LiGeA:CCLE_388, LINCS_LDP:LCL-1885,
PharmacoDB:MKN7_939_2019, PRIDE:PXD030304, Progenetix:CVCL_1417,
PubChem_Cell_line:CVCL_1417, RCB:RCB0999, RCB:RCB3687, TKG:TKG 0228,
Wikidata:Q54905831

ID: CVCL_1417

Record Creation Time: 20220427T220810+0000

Record Last Update: 20260905T181149+0000

Ratings and Alerts

No rating or validation information has been found for MKN7.

Warning: Discontinued: JCRB; JCRB0082

Caution: TP53 mutation indicated incorrectly as being at p.Ile251Leu (c.751A>C) in PubMed=15900046., Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Warning: Discontinued: JCRB; FDSC0010

Caution: TP53 mutation indicated incorrectly as being at p.Ile251Leu (c.751A>C) in PubMed=15900046., Population: Japanese., Part of: JFCR45 cancer cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Xie YL, et al. (2026) Ubiquitin Specific Peptidase 48 Deubiquitinates METTL3 to Modulate Ferroptosis in Gastric Cancer Cells. *Molecular carcinogenesis*.

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

Pan G, et al. (2026) MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. *Molecular cancer*, 25(1).

Ishida M, et al. (2026) AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. *NPJ precision oncology*, 10(1).

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. *Molecular cancer therapeutics*, 24(9), 1295.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. *Cellular oncology (Dordrecht, Netherlands)*, 48(6), 1837.

Mano Y, et al. (2025) DNA-hypermethylated human gastric cancer circumvents apoptosis in the absence of TP53 mutation. *The Journal of pathology*, 267(4), 435.

Zenz T, et al. (2025) The Histone Deacetylase Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2-Amplified Tumors and in Combination Therapies. *Cancer research and treatment*, 57(3), 781.

Zenz T, et al. (2025) Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. *Neoplasia (New York, N.Y.)*, 60, 101121.

Wei Q, et al. (2024) Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(5), 984.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Park J, et al. (2023) Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. *Scientific reports*, 13(1), 22648.

Umeda S, et al. (2022) Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, 25(3), 558.

Tanaka H, et al. (2022) Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of

recurrence after surgery and subsequent chemotherapy. Journal of gastroenterology, 57(9), 640.

Hirano T, et al. (2020) FARP1 boosts CDC42 activity from integrin α_5 signaling and correlates with poor prognosis of advanced gastric cancer. Oncogenesis, 9(2), 13.